These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 10904462

  • 1. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.
    McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD.
    Arch Intern Med; 2000 Jul 24; 160(14):2185-91. PubMed ID: 10904462
    [Abstract] [Full Text] [Related]

  • 2. [Pharmacological therapy of obesity].
    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.
    G Ital Cardiol (Rome); 2008 Apr 24; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR.
    J Hum Hypertens; 2002 Jan 24; 16(1):13-9. PubMed ID: 11840225
    [Abstract] [Full Text] [Related]

  • 4. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM.
    Clin Ther; 2006 May 24; 28(5):770-82. PubMed ID: 16861099
    [Abstract] [Full Text] [Related]

  • 5. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, Sibutramine in Hypertensives Clinical Study Group.
    J Hum Hypertens; 2002 Jan 24; 16(1):5-11. PubMed ID: 11840224
    [Abstract] [Full Text] [Related]

  • 6. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.
    Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP, Sibutramine/Diabetes Clinical Study Group.
    Diabetes Obes Metab; 2000 Jun 24; 2(3):175-87. PubMed ID: 11220553
    [Abstract] [Full Text] [Related]

  • 7. Weight loss in obese African American and Caucasian adolescents: secondary analysis of a randomized clinical trial of behavioral therapy plus sibutramine.
    Budd GM, Hayman LL, Crump E, Pollydore C, Hawley KD, Cronquist JL, Berkowitz RI.
    J Cardiovasc Nurs; 2007 Jun 24; 22(4):288-96. PubMed ID: 17589281
    [Abstract] [Full Text] [Related]

  • 8. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
    Dujovne CA, Zavoral JH, Rowe E, Mendel CM, Silbutramine Study Group.
    Am Heart J; 2001 Sep 24; 142(3):489-97. PubMed ID: 11526363
    [Abstract] [Full Text] [Related]

  • 9. Long-term weight loss with sibutramine: a randomized controlled trial.
    Wirth A, Krause J.
    JAMA; 2001 Sep 19; 286(11):1331-9. PubMed ID: 11560538
    [Abstract] [Full Text] [Related]

  • 10. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.
    James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, Saris WH, Van Gaal LF.
    Lancet; 2001 Sep 19; 356(9248):2119-25. PubMed ID: 11191537
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study.
    Halpern A, Leite CC, Herszkowicz N, Barbato A, Costa AP.
    Rev Hosp Clin Fac Med Sao Paulo; 2002 Sep 19; 57(3):98-102. PubMed ID: 12118266
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R.
    Diabetes Obes Metab; 2005 Jan 19; 7(1):47-55. PubMed ID: 15642075
    [Abstract] [Full Text] [Related]

  • 13. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
    Fanghänel G, Cortinas L, Sánchez-Reyes L, Berber A.
    Int J Obes Relat Metab Disord; 2001 May 19; 25(5):741-7. PubMed ID: 11360159
    [Abstract] [Full Text] [Related]

  • 14. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity.
    Fanghänel G, Cortinas L, Sánchez-Reyes L, Berber A.
    Int J Obes Relat Metab Disord; 2000 Feb 19; 24(2):144-50. PubMed ID: 10702763
    [Abstract] [Full Text] [Related]

  • 15. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
    Scholze J, Grimm E, Herrmann D, Unger T, Kintscher U.
    Circulation; 2007 Apr 17; 115(15):1991-8. PubMed ID: 17404163
    [Abstract] [Full Text] [Related]

  • 16. Effects of sibutramine treatment in obese adolescents: a randomized trial.
    Berkowitz RI, Fujioka K, Daniels SR, Hoppin AG, Owen S, Perry AC, Sothern MS, Renz CL, Pirner MA, Walch JK, Jasinsky O, Hewkin AC, Blakesley VA, Sibutramine Adolescent Study Group.
    Ann Intern Med; 2006 Jul 18; 145(2):81-90. PubMed ID: 16847290
    [Abstract] [Full Text] [Related]

  • 17. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.
    Clin Ther; 2004 Sep 18; 26(9):1427-35. PubMed ID: 15531005
    [Abstract] [Full Text] [Related]

  • 18. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.
    Smith IG, Goulder MA, Sibutramine Clinical Study 1047 Team.
    J Fam Pract; 2001 Jun 18; 50(6):505-12. PubMed ID: 11407998
    [Abstract] [Full Text] [Related]

  • 19. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE, Ruiz AM, Monsalve MC, Berber A.
    Obes Res; 2000 Jan 18; 8(1):71-82. PubMed ID: 10678261
    [Abstract] [Full Text] [Related]

  • 20. [Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial].
    Tong NW, Ran XW, Li QF, Tang BD, Li R, Yang FY, Liu YP, Li XJ.
    Zhonghua Nei Ke Za Zhi; 2005 Sep 18; 44(9):659-63. PubMed ID: 16202254
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.